<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073303</url>
  </required_header>
  <id_info>
    <org_study_id>1789-301-008</org_study_id>
    <nct_id>NCT04073303</nct_id>
  </id_info>
  <brief_title>BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence</brief_title>
  <official_title>BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and effectiveness of administering BOTOX for&#xD;
      the treatment of Masseter Muscle Prominence (MMP) in adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">November 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of responders that show change in masseter muscle prominence (MMP)</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Investigator assessment of severity of MMP using the Masseter Muscle Prominence Scale (MMPS). Score ranges from 1 = minimal to 5 = very marked</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 18 Months</time_frame>
    <description>The number of patients who experienced one or more AEs during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital sign values (blood pressure, respiratory rate, and pulse rate)</measure>
    <time_frame>Up to 18 Months</time_frame>
    <description>Summary statistics of change from baseline vital sign values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders who achieve a clinical target on a MMP scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Investigator assessment of MMP using a scale ranging from minimal to very marked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders who achieve improvement using a self-assessment scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Improvement of MMP is self-assessed by the participant using a scale ranging from not at all pronounced to very pronounced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders that show improvement in MMP</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Improvement of MMP is self-assessed by the participant using a scale for change in MMP ranging from much improved to much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lower facial width</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Calculated from standardized images, measured in millimeters (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment effect</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>Improvement from baseline of MMP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Masseter Muscle Prominence</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A (BOTOX®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Day 1 Administration of bilateral intramuscular injections into the masseter</description>
    <arm_group_label>Botulinum Toxin Type A (BOTOX®)</arm_group_label>
    <other_name>OnabotulinumtoxinA</other_name>
    <other_name>BOTOX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Masseter prominence at the Day 1 visit&#xD;
&#xD;
          -  BMI ≤ 30 kg/m2 using the calculation: BMI = weight (kg)/[height (m)]2&#xD;
&#xD;
          -  A female participant must be willing to minimize the risk of inducing pregnancy for&#xD;
             the duration of the clinical study and follow-up periods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition that may put the participant at increased medical risk with&#xD;
             exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome,&#xD;
             amyotrophic lateral sclerosis, or any other condition that might interfere with&#xD;
             neuromuscular function&#xD;
&#xD;
          -  An anticipated need for surgery or overnight hospitalization during the study&#xD;
&#xD;
          -  An anticipated need for treatment with botulinum toxin of any serotype for any&#xD;
             indication during the study (other than study intervention)&#xD;
&#xD;
          -  History of dental or surgical procedure for lower facial shaping or masseter muscle&#xD;
             reduction&#xD;
&#xD;
          -  Prior mid-facial and/or lower facial treatment with nonpermanent soft tissue fillers,&#xD;
             synthetic implantations, autologous fat transplantation, fat-reducing injectables,&#xD;
             and/or skin-tightening laser treatments within 6 months prior to Day 1&#xD;
&#xD;
          -  Prior exposure to botulinum toxin of any serotype to the masseter muscle or lower face&#xD;
             at any time, or to any other part of the body within the 6 months prior to Day 1&#xD;
&#xD;
          -  History of temporomandibular joint disorder (TMJD)&#xD;
&#xD;
          -  Masseter prominence due to other etiologies (eg, parotid gland infection, parotiditis,&#xD;
             malignancy)&#xD;
&#xD;
          -  Known allergy or sensitivity to any of the components of the study treatments or any&#xD;
             materials used in the study procedures&#xD;
&#xD;
          -  History of alcohol or drug abuse within 12 months of Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beacon Dermatology Inc /ID# 233018</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3E 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carruthers &amp; Humphrey Clinical Research /ID# 232764</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Derm /ID# 233156</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Dermatology /ID# 233001</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital /ID# 233148</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital /ID# 233072</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital /ID# 232973</name>
      <address>
        <city>Xicheng District</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233008</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University /ID# 232836</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital /ID# 233087</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of XI'AN Jiaotong University /ID# 232835</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710049</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University /ID# 233027</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University /ID# 233107</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital /ID# 233016</name>
      <address>
        <city>Nanjing Jiangsu</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medcine /ID# 232656</name>
      <address>
        <city>Shanghai</city>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital /ID# 232961</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital /ID# 233080</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 233033</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 233133</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital /ID# 233009</name>
      <address>
        <city>Taipei City</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

